4.6 Article

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study

期刊

GYNECOLOGIC ONCOLOGY
卷 113, 期 2, 页码 264-269

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2009.01.002

关键词

Genetic polymorphisms; Taxanes; Platinum compounds; Epithelial ovarian cancer

资金

  1. Medical Research Collaborating Center (MRCC) in Seoul National University Hospital
  2. Cancer Research Institute, Seoul National University Research Fund [CRI-06-3]

向作者/读者索取更多资源

Objective. We sought to evaluate the affect of genetic polymorphisms on clinical outcomes in patients with epithelial ovarian cancer (EOC). Methods. Clinical data of 118 patients between March 2001 and November 2006 were reviewed. They underwent staging laparotomy followed by adjuvant chemotherapy using taxanes and platinum compounds. We investigated ERCC1 N118N, ERCC1 8092C>A, ERCC2 K751Q, XRCC1 R399Q, XRCC1 R194W, ABCB1 3435C>T ABCB1 2677G>T/A, GSTP1 1105V, GSTM1 and GSTT1 polymorphisms with single base primer assay. Results. The multivariate logistic regression analysis revealed that non-null genotype in GSTT1 polymorphism was a poor prognostic factors for overall response (adjusted OR, 0.29: 95% CI, 0.17-0.67), and A/A genotype in GSTP1 1105V polymorphism and T/T or T/A or A/A genotype in ABCB1 2677G>T/A polymorphism were significant risk factors for grade 3 or 4 hematological (adjusted OR, 3.08; 95% CI, 1.128.43) and gastrointestinal toxicities (adjusted OR, 9.74; 95% CI, 1.59-15.85), respectively. Moreover, The multivariate Cox's proportional hazard regression analysis showed that C/A or A/A genotype in ERCC1 8092C>A polymorphism and non-null genotype in GSTT1 polymorphism were prognostic factors for poor progression-free survival (adjusted HR, 1.94; 95% CI, 1.07-3.51) and poor overall survival (adjusted HR, 1.65; 95% CI, 1.79-3.42), respectively. Conclusion. Genetic polymorphisms such as ERCC1 8092C>A, ABCB1 2677G>T/A, GSTP1 1105V and GSTT1 polymorphisms may affect drug response, toxicity and survival in patient with EOC who received taxane- and platinum-based chemotherapy after surgery. However, large-scale, prospective clinical studies are required for evaluating the role of genetic polymorphisms. (C) 2009 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据